Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and no new safety concerns in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from an ongoing open-label extension phase of a global Phase…
Discussion
It’s taken me three months to have enough distance and perspective to tell you about my once-in-a-lifetime trip that didn’t happen. I was all set to visit a favorite relative in Rome, with plans to stay in the dormitory of a 17th-century church with nuns. It was my first trip…
Discussion
Subjective, patient-reported data on lived experiences should always be considered in the care of chronic conditions like multiple sclerosis (MS), according to a recent presentation. In a survey, many people with MS reported feeling that their lived experiences aren’t given enough consideration during visits with their care providers, and…
Discussion
This article was provided by our partner, Can Do MS. It has been reviewed by Bionews for accuracy and relevance. The views and opinions expressed are those of the author and do not necessarily reflect the views of Bionews or Multiple Sclerosis News Today. There’s a moment when you…
Discussion
I am attending the annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) this week, my second time here. Like my first time, in 2024, I’m going as a member of the multiple sclerosis (MS) committee of the Paralyzed Veterans of America. Back then, I thought all…
Get regular updates to your inbox.
